A groundbreaking review of two decades of research reveals that type 2 diabetes, atherosclerosis (hardening of the arteries), and cancer manipulate the same cellular machinery when tissues don't get enough oxygen. This discovery opens the door to treating multiple diseases with a single approach, potentially transforming how doctors tackle some of the world's deadliest conditions. What's Really Happening Inside Your Cells When Oxygen Runs Low? When tissues don't receive enough oxygen, cells activate a survival program controlled by proteins called hypoxia-inducible factors, or HIF for short. Think of HIF as a cellular alarm system that switches on when oxygen becomes scarce. Researchers have identified two main types: HIF-1 alpha and HIF-2 alpha. HIF-1 alpha kicks in during acute oxygen shortages and triggers inflammation and energy production through a process called glycolysis. HIF-2 alpha takes over during chronic low-oxygen conditions and promotes blood vessel growth and adaptation. The problem is that cancer cells, inflamed fat tissue in obese individuals, and damaged arteries all exploit this same oxygen-starved state to their advantage. Understanding this shared vulnerability could lead to treatments that work across all three diseases. How Do These Three Diseases Use the Same Cellular Trick? The research identifies a specific pattern repeating across type 2 diabetes, atherosclerosis, and cancer. In each condition, low oxygen triggers the same cascade of events, though the consequences differ by location. In type 2 diabetes and obesity, expanding fat tissue becomes starved for oxygen. This triggers immune cells called macrophages to shift into an inflammatory state that perpetuates low-grade inflammation throughout the body. These activated macrophages recruit additional inflammatory cells and prevent the normal healing process that should calm inflammation down. The result is sustained tissue damage and worsening metabolic dysfunction. In atherosclerosis, the lipid-rich core of arterial plaques becomes oxygen-deprived. Low oxygen stabilizes HIF-1 alpha, which ramps up the production of enzymes called matrix metalloproteinases (MMP-2 and MMP-9). These enzymes break down the protective fibrous cap that keeps plaques stable. Simultaneously, the same low-oxygen state reduces cholesterol removal from the plaque, weakening the artery wall further and increasing the risk of heart attacks and strokes. In cancer, poorly vascularized tumor regions accumulate two metabolic byproducts: lactate and succinate. Lactate activates immune-suppressing tumor-associated macrophages (TAMs), while succinate signals through a receptor called SUCNR1 to reinforce the same HIF-1 alpha pathway. Together, these molecules create an immunosuppressive microenvironment that allows tumors to hide from the immune system and express PD-L1, a protein that acts like an invisibility cloak. What Role Do Exosomes Play in This Disease Connection? Exosomes are tiny cellular packages that cells release to communicate with neighboring cells. In low-oxygen environments, cells package specific microRNAs (small regulatory molecules) into exosomes. One particularly important microRNA is miR-301a-3p. When these exosomes deliver this microRNA to macrophages, it suppresses a protein called PTEN and activates a pathway called PI3K-gamma. This amplifies immune suppression and increases PD-L1 expression, making it harder for the immune system to fight cancer cells. This exosome-based communication system operates across all three diseases, suggesting that blocking this pathway could have broad therapeutic benefits. Ways to Target This Shared Cellular Weakness Researchers have identified several drug targets that could interrupt the oxygen-starvation pathway across multiple diseases: - HIF-2 Alpha Inhibitors: Drugs like belzutifan selectively block HIF-2 alpha, preventing the adaptive responses that allow tissues to survive without oxygen. This approach shows promise in cancer and may help reduce inflammation in metabolic diseases. - PI3K-Gamma Blockade: Inhibiting the PI3K-gamma pathway could reduce immune suppression in tumors and dampen inflammatory macrophage activation in fat tissue and arterial plaques. - SUCNR1 Targeting: Blocking the succinate receptor SUCNR1 could prevent cancer cells from creating an immunosuppressive environment and reduce macrophage activation in atherosclerotic plaques. - Exosome-Based MicroRNA Modulation: Therapies that intercept or neutralize immunosuppressive microRNAs in exosomes could restore immune function in cancer patients and reduce inflammation in metabolic diseases. Can Doctors Measure Treatment Success With a Simple Blood Test? The research proposes a practical biomarker panel that physicians could use to assess how well these new treatments work. The panel includes three key measurements: HIF-1 alpha levels, vascular endothelial growth factor A (VEGF-A), and matrix metalloproteinase-9 (MMP-9). Together, these markers reflect the overall oxygen burden in tissues, the state of macrophage programming, and how well a treatment is working. This approach could simplify clinical monitoring and help doctors quickly determine whether a patient is responding to therapy. Rather than waiting months for disease-specific outcomes, physicians might track these universal markers across diabetes, heart disease, and cancer patients. What Makes This Research Different From Previous Studies? This comprehensive review analyzed peer-reviewed research published between 2003 and 2025, drawing from major medical databases including PubMed, Scopus, and Web of Science. The researchers prioritized mechanistic studies that explained how diseases work at the cellular level and translational research that bridges laboratory findings to clinical applications. By integrating evidence across three seemingly unrelated diseases, the review reveals a unifying principle: oxygen scarcity reprograms immune cells in ways that benefit disease progression. This systems-level perspective suggests that future treatments might work across multiple conditions simultaneously, potentially reducing the number of medications patients need to take. What's the Next Step for Patients? While these drug targets show promise in research settings, most are still in clinical trials or early development stages. Patients with type 2 diabetes, atherosclerosis, or cancer should continue following their current treatment plans and discussing new options with their healthcare providers. The identification of this shared cellular pathway represents a significant conceptual advance that could reshape treatment strategies over the next five to ten years. For researchers and pharmaceutical companies, this work provides a clear roadmap for drug development. Rather than creating separate treatments for each disease, companies can now focus on therapies that target the underlying oxygen-starvation mechanism. This approach could accelerate drug discovery and bring new treatments to patients faster than traditional disease-specific research.
